bioAffinity Technologies (BIAFW) Change in Accured Expenses (2021 - 2026)

bioAffinity Technologies has disclosed Change in Accured Expenses across 6 years of filings, most recently posting $310857.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 1210.72% year-over-year to $310857.0; the TTM figure through Mar 2026 stood at $658111.0 (up 35.02% YoY), while the FY2025 annual figure was $319267.0, up 28.27% from the prior year.
• Change in Accured Expenses slipped to $310857.0 in Q1 2026, from $733442.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for BIAFW reached as high as $733442.0 in Q4 2025 and fell as low as -$399318.0 in Q4 2022.
• The 5-year median for Change in Accured Expenses is -$27987.0 (2025), against an average of $76904.8.
• Annual changes were most pronounced in 2025 — Change in Accured Expenses slumped 476.22% — and 2026, when it surged 1210.72%.
• A 5-year view of Change in Accured Expenses shows it stood at -$399318.0 in 2022, then jumped by 226.72% to $506025.0 in 2023, then fell by 2.28% to $494470.0 in 2024, then soared by 48.33% to $733442.0 in 2025, then slumped by 57.62% to $310857.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $310857.0, $733442.0, and -$63487.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.